ABSTRACT The influence of a systemic lytic state on reperfusion obtained after intracoronary streptokinase (SK) therapy has been evaluated in 15 patients with acute myocardial infarction and complete coronary occlusion. Coronary angiographic studies and measurements of blood fibrinolytic parameters were repeated at 15 min intervals during the infusion of a standard dose of SK and were compared with the results with approximately one-tenth the standard dose. Successful reperfusion was obtained in only 20% (2/10) of patients receiving the low dose, compared with a 75% to 80% success rate in patients receiving the standard dose as initial treatment (4/5) or as follow-up treatment of patients in whom low-dose therapy failed (6/8 THE RATIONALE for regional thrombolytic treatment of coronary arterial thrombosis is that a high local concentration of plasminogen activator can induce maximal thrombolysis with minimal systemic effect in the blood and a low incidence of hemorrhagic complication. Implicit in this approach are the assumptions that the activator is relatively restricted to the region of the thrombus and that its concentration in the blood is below a critical threshold that would affect plasma coagulation. However, greater therapeutic efficacy and decreased risk of bleeding have not been proved by comparative trial of systemic vs regional treatment, 562 nor has the exact dose of activator required to achieve a restricted local effect been determined by a dose-response study. Furthermore, the available studies do not clearly demonstrate superior results with local infusions. Early studies with streptokinase (SK) have used both regional perfusions into the coronary ostial and intravenous administration2 in patients with acute myocardial infarction. These studies suggested efficacy of both local and systemic infusion, albeit without the benefit of angiographic documentation. The dramatic demonstration by Rentrop et al.3 4 of coronary arterial reperfusion after intracoronary administration of SK stimulated others to adopt such an approach.5-10 However, the intracoronary SK dosage was high, equivalent to that used intravenously for the treatment of deep vein thrombosis, pulmonary embolism, or peripheral arterial occlusion," 12 suggesting that regional localization of SK may not have been accomplished in the reported successes. Although the incidence of CIRCULATION
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Early studies with streptokinase (SK) have used both regional perfusions into the coronary ostial and intravenous administration2 in patients with acute myocardial infarction. These studies suggested efficacy of both local and systemic infusion, albeit without the benefit of angiographic documentation. The dramatic demonstration by Rentrop et al.3 4 of coronary arterial reperfusion after intracoronary administration of SK stimulated others to adopt such an approach.5-10 However, the intracoronary SK dosage was high, equivalent to that used intravenously for the treatment of deep vein thrombosis, pulmonary embolism, or peripheral arterial occlusion," 12 suggesting that regional localization of SK may not have been accomplished in the reported successes. Although the incidence of hemorrhagic complication was low, a drop in mean plasma fibrinogen3 suggests that the plasma coagulation system was deranged by a systemic SK effect, despite the intracoronary route of administration. In fact, a significant reduction in plasma fibrinogen of more than 70% has been observed in the great majority of patients treated with "low dose" regional SK infusion. '3' 14 Thus several questions remain unanswered regarding the comparative safety and efficacy of regional and systemic therapy. First, does regional infusion by current regimens limit the fibrinolytic effect to the occluded vessel and avoid systemic fibrinogenolysis? Second, if the effect is limited, can lysis of the offending thrombus still be achieved? Third, is a systemic effect more than an undesirable accompaniment of treatment, or may it actually contribute to the desired thrombolytic potential of regional treatment? In the studies reported here, we have addressed these issues by correlating angiographic reperfusion with a systemic lytic state in patients with acute myocardial infarction receiving intracoronary thrombolytic therapy with SK. Treatment with standard-dose SK was compared with results obtained with approximately one-tenth this dose. Angiographic and hematologic studies followed at 15 min intervals to assess vascular patency and blood fibrinolytic parameters.
Methods
Fifteen patients who presented between September 1982 and April 1983 with signs and symptoms of acute transmural myocardial infarction constituted the study population. Acute transmural myocardial infarction was defined as prolonged chest pain unrelieved by nitroglycerin and with electrocardiographic evidence of persistent ST segment elevation, reciprocal ST segment depression, and minimal or no Q wave formation. Patients were excluded if the duration of symptoms was greater than 8 hr from the onset of pain to the time of therapy or if there was any contraindication to the use of thrombolytic therapy. Patients were evaluated initially in the emergency room or on the hospital ward, and if the entry criteria were fulfilled, written informed consent as approved by the Committee on Investigations Involving Human Subjects of the Strong Memorial Hospital was obtained before randomization.
All subjects were pretreated with 100 mg iv hydrocortisone, 50 mg iv diphenhydramine hydrochloride, and 70 to 100 mg iv lidocaine with a 2 mg/min infusion that was further titrated to control ventricular ectopy as needed. Routine cardiac catheterization by the Judkins approach was performed, including left ventriculography in the 30 degree right anterior oblique projection and coronary angiography. The uninvolved coronary artery was cannulated first, then the artery that appeared to supply the infarct zone by electrocardiographic evidence. Only patients with complete coronary occlusion were admitted to the study and randomly assigned to a treatment group. Catheter exchanges were performed through No. 8F introducer, which was maintained in the femoral artery with a sidearm attachment for drawing blood and monitoring pressure during SK infusion. Once the occluded coronary artery was identified, the intracoronary infusion of SK (Streptase, Hoechst-Roussel PharmaceutiVol. 71, No. 3, March 1985 cals, Somerset, NJ, or Kabikinase, Pharmacia, Piscataway, NJ) was begun with a Harvard pump. Subselective coronary infusion catheters were not used.
Initially, patients were randomly assigned to three SK treatment groups: standard dose (20,000 U bolus and 4000 U/min infusion), low dose (about 1/10 standard), and very low dose (about 1/20 standard). Because the infusion catheters were flushed by contrast medium in performance of follow-up angiograms, the actual infusion dosages were higher than anticipated (see table 1), and the total dosages in the low-dose and very lowdose categories were not distinguishable. Therefore the two experimental groups were combined into a single low-dose treatment category (1000 or 2000 U bolus and 300 to 1200 U/min infusion) for purposes of analysis. The infusion was interrupted every 15 min or after a cardiac event, such as increased ventricular ectopy or sudden bradyarrhythmia, to perform coronary angiographic studies. Patients assigned to standard-dose SK received 45 to 60 min of treatment (except patient 1, who received 120 min of treatment), at which time therapy was discontinued if there was no evidence of thrombolysis. Patients assigned to low-dose SK received a minimum of 45 min of therapy. To provide the potential benefit of approved thrombolytic therapy for all patients, those patients in whom reperfusion was not achieved on low-dose SK by 45 min were retreated with standard-dose SK. After the additional 45 min of standarddose SK, therapy was terminated if thrombolysis had not occurred. In patients in whom thrombolysis was achieved, the SK infusion was continued until no further improvement was demonstrated in the luminal diameter of the involved vessel, as assessed by coronary angiography every 15 min to a maximum treatment duration of 120 min.
Upon completion of SK administration, a bolus injection of heparin (5000 U) was given intravenously and a continuous infusion was begun, maintaining the partial thromboplastin time at approximately twice control. Lidocaine infusion was maintained for at least 24 hr. The introducer remained in the femoral artery to improve hemostatic control and to provide pressure monitoring for approximately 24 hr, at which time coronary angiography and ventriculography were repeated. If the previously occluded coronary artery remained patent, heparin therapy was continued, replaced by warfarin after approximately 1 week. Antiplatelet agents were not routinely used. Only one patient had bleeding associated with treatment, which was localized to the femoral arterial catheterization site.
Laboratory evaluation included a baseline SK resistance test, 15 fibrinogen level, 16 regard to age (58 ± 3 vs 59 ± 2 yr), delay after onset of symptoms (4.4 ± 0.8 vs 4.0 ± 0.6 hr), fibrinogen concentration (424 ± 53 vs 335 ± 25 mg/dl), or total plasma SK resistance (24,000 + 6000 vs 33,000 + 3000 U), nor was there a difference in infarct location (2:3 ratio of anterior to inferior in both groups) or male preponderance (4:1 vs 10:0). The ratio of right coronary (plus circumflex) arterial occlusion to left anterior descending arterial occlusion was identical, although there was a higher incidence of concomitant coronary artery disease in the low-dose SK group (80% vs 40%). The cumulative dose of SK administered to each patient is illustrated in figure 1 and table 2. The mean standard-dose rate was approximately sixfold greater than the low-dose rate (4204 ± 178 vs 736 ± 84 U/min). Patients who experienced treatment failure at low dose, defined as no reperfusion within 45 min or reocclusion during infusion, were retreated with the standard-dose regimen. The mean dose rate for these eight patients (3570 ± 259 U/min) was similar to the initial standard-dose rate. Reperfusion was achieved in four of five patients receiving the standard dose after 46 ± 18 min, at which time 206,000 ± 80,000 U of SK had been administered. By contrast, stable reperfusion was achieved in only two (Nos. 3 and 8) of 10 patients receiving low-dose SK after an infusion time of 15 The SK doses administered to the three patients who had no reperfusion and to the 12 successfully treated patients are illustrated in figure 2. There was a wide variation in SK dose at the time of the initial coronary reperfusion, ranging from a low of only 8000 U (patient 8) to over 400,000 U (patient 1). Three of the 12 patients experienced reocclusion at 45, 30, and 31 min after initial reperfusion, when the total administered SK dose was 50,000 to 60,000 U ( 4 (see figure 3) were assessed. Two of the five patients at the time.
showed a significant decrease in f3:y ratio of greater on at a truly than 20%, although the fibrinogen concentration was 16,000 and unchanged. This indicated that nine rather than seven )nly 64,000 of the 12 patients had degradation of plasma fibrinogen nterval. Exat the time of (rather than after) reperfusion, further dministered decreasing the possibility of significant SK specificity failed was on the fibrin substrate. However, the SK dose required to produce reperfusion was significantly different in the two groups. An apparently more sensitive group of thrombi, in which reperfusion occurred first, lysed at a mean SK dose of 47,000 U, which was significantly lower than the mean dose of 204,000 U (p < .005) at which a more resistant group lysed.
Discussion
The reperfusion success rate of SK therapy was strikingly lower with the low-dose regimen (20%), as compared to that with standard-dose intracoronary SK (80%). Retreatment of the patients in whom low-dose treatment failed (8/10) with standard-dose SK resulted in the same reperfusion rate (75%) as initial treatment with the standard dose, a success rate (table 3) that was comparable to the experience of others with this dose regimen.3-10. 14. [21] [22] [23] [24] [25] [26] [27] [28] [29] This difference could not be explained by skewing of the known pretreatment clinical or laboratory risk factors, such as the delay before treatment or unusual resistance to SK, and could be ASuccessful treatment in 12 patients includes six who responded to initial infusions of low-(n = 2) or standard-dose SK (n = 4) plus six who responded to retreatment at standard dose after failure at low-dose SK.
attributed only to the lower dose regimen. One possible explanation for the high failure rate at the low dose was that an inadequate amount of activator was provided. This was unlikely in view of the fact that onehalf of the treatments with the low-dose regimen (5110) produced a lytic state ( figure 3 .
the SK infusion and to show the rapid and strict correlation of the two events.
Although the limited dose of SK was the primary reason for the absence of a lytic state, the association with failure to cause reperfusion was maintained regardless of whether standard-or low-dose SK was administered. This dose-response association with the standard SK dose was best illustrated in patients 5, 6, and 14, who experienced no reperfusion. Two of these three patients did not develop a lytic state and the total dose of SK received (mean 173,000 U) was lower than that for most of the successfully treated patients ( figure  2 ). This suggests that a dose of approximately 200,000 U of SK may represent the necessary threshold required to induce reperfusion with regional administration. Although our observations (figure 1) suggest that initial thrombolysis usually occurs after administration of about 100,000 U, in agreement with the data of This effective intracoronary dose may be less than is required for intravenous use,'4 31-33 although no prospective or randomized dose-ranging comparison has been reported. Furthermore, the experience to date in mostly uncontrolled studies suggests a lower overall response to an intravenous dose of 500,000 to 1,500,000 U (50% success) than to an intracoronary dose of 200,000 to 500,000 U (70% to 75% success). 29 The overall conclusions of our study are compatible with the assumption that intrinsic properties of the thrombi are of primary importance in determining response to treatment, that a minimal dose of agent is needed to achieve success in the sensitive thrombi, and that a systemic effect after intracoronary treatment is a regular accompaniment and perhaps a necessary requirement for attaining successful reperfusion. The results provide a laboratory foundation for the concept that intravenous SK administration may induce coronary reperfusion as regularly as intracoronary SK infusion.
